Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events

Gillian L. Booth,[*] Elaine E.L. Wang,[†] with the Canadian Task Force on Preventive Health Care[‡]

Abstract

Objective: To establish guidelines for the screening and treatment of hyperhomocysteinemia in the investigation and management of coronary artery disease (CAD).

Options: Measurement of plasma total homocysteine (tHcy) levels in the fasting state or 4–6 hours after oral methionine load; vitamin supplementation with folic acid and vitamins B_6 and B_{12}; adherence to the recommended daily allowance of dietary sources of folate and vitamins B_6 and B_{12}.

Outcomes: This article reviews the available evidence on the association between plasma tHcy levels and CAD and the effect of lowering tHcy levels through vitamin supplementation or dietary intake.

Evidence: MEDLINE was searched for relevant English-language articles published from January 1966 to June 1999; also reviewed were additional articles identified from the bibliographies.

Benefits, harms and costs: Cardiovascular disease is the leading cause of death in Canada. Homocysteine, generated in the metabolism of methionine, may have a role in the development of cardiovascular disease. The prevalence of hyperhomocysteinemia in the general population is between 5% and 10% and may be as high as 30%–40% in the elderly population. If population-based studies are correct, tHcy may be responsible for up to 10% of CAD events and thus may represent an important and potentially modifiable risk factor for cardiovascular disease. Laboratory testing for tHcy is currently restricted to research centres, and costs range from $30 to $50 per person. Newer, less costly techniques have been developed and should become readily available with time.

Values: The strength of evidence was evaluated using the methods of the Canadian Task Force on Preventive Health Care.

Recommendations: Although there is insufficient evidence to recommend the screening or management of hyperhomocysteinemia at present (grade C recommendation), adherence to recommended daily allowance of dietary sources of folate and vitamins B_{12} and B_6 should be encouraged. If elevated tHcy levels are discovered, vitamin deficiency should be ruled out to allow specific treatment and prevention of complications, such as neurological sequelae due to vitamin B_{12} deficiency. Experts in the field advocate treatment of elevated tHcy levels in high-risk people, such as those with a personal or family history of premature atherosclerosis or a predisposition to develop hyperhomocysteinemia. Definitive guidelines for the management of hyperhomocysteinemia await the completion of randomized trials to establish the effect of vitamin supplementation on CAD events.

Validation: The findings of this analysis were reviewed through an iterative process by the members of the Canadian Task Force on Preventive Health Care.

Sponsors: The Canadian Task Force on Preventive Health Care is funded through a partnership between the Provincial and Territorial Ministries of Health and Health Canada.

Research

Recherche

From the Departments of *Medicine and †Pediatrics, Clinical Epidemiology and Health Care Research Program, University of Toronto, Toronto, Ont.

‡Formerly the Canadian Task Force on the Periodic Health Examination. The list of task force members appears at the end of the article.

This article has been peer reviewed.

CMAJ 2000;163(1):21-9

See related article page 37

Return to July 11, 2000 Table of Contents

Cardiovascular disease is the leading cause of death in Canada, accounting for almost 40% of all deaths.[1] Although rates of death from ischemic heart disease are declining,[2] the costs to society remain high. Since a number of cardiovascular deaths may be preventable, the search for novel risk factors continues. Homocysteine is an intermediate that is generated in the metabolism of methionine (Fig. 1). Several intriguing observations suggest a role for homocysteine in the development of vascular disease. People who have homocystinuria,[3] an autosomal recessive disorder, have severe hyperhomocysteinemia, premature atherosclerosis and thromboembolic complications.[4] Furthermore, homocysteine may promote the oxidation of low-density lipoprotein cholesterol, vascular smooth muscle cell proliferation, platelet and coagulation factor activation, and endothelial dysfunction.[5–7] Therefore, altered homocysteine metabolism has become the focus of increasing attention because of its potential role in the pathogenesis of atherosclerosis and other conditions, such as venous thrombosis.[8,9]

The prevalence of hyperhomocysteinemia in the general population is between 5% and 10%, according to a threshold set at the 90th or 95th percentile (about 15 μmol/L).[7] However, rates may be as high as 30%–40% in the elderly population.[10] If the results from population-based studies are correct, then up to 10% of events due to coronary artery disease (CAD) may be attributable to elevated plasma homocysteine levels.[11] Thus, homocysteine may represent an important and potentially modifiable risk factor for cardiovascular disease.

The purpose of this review was to evaluate the quality of evidence pertaining to homocysteine and CAD events and to make recommendations regarding the screening and management of hyperhomocysteinemia.

Methods

A computerized search of MEDLINE for English-language articles published between January 1966 and June 1999 was conducted using the MeSH (medical subject heading) terms "homocysteine," "hyperhomocysteinemia," "methionine," "coronary disease," "arteriosclerosis," "myocardial ischemia," "folic acid," "vitamin B_{12}," "vitamin B_6," and "pyridoxine" in various combinations. Relevant articles were also identified through a manual review of references. Where possible, the highest level of evidence was sought; hence, abstracts, cross-sectional studies, case reports and case series were not included. Studies concerning other types of vascular disease were also excluded.

The evidence was reviewed systematically using the methodology of the Canadian Task Force on Preventive Health Care. The task force, comprised of expert clinicians and methodologists from a variety of medical specialties, used a standardized evidence-based method (Appendix 1) for evaluating the effectiveness of this intervention. The final recommendations were arrived at unanimously by an expert panel and principal author. Feedback from 2 content experts was incorporated into a final draft of the manuscript before submission for publication. Procedures to achieve adequate documentation, consistency, comprehensiveness, objectivity and adherence to the task force's methodology were main-



Fig. 1: Biochemical pathways of homocysteine metabolism. Ser = serine; Gly = glycine; MTHF = methylenetetrahydrofolate; MTHFR = N^5,N^{10}-methylenetetrahydrofolate reductase; THF = tetrahydrofolate; SAM = *S*-adenosylmethionine; SAH = *S*-adenosylhomocysteine; DMG = dimethylglycine; CβS = cystathionineβ-synthase.

tained at all stages during review development, the consensus process and production of the final manuscript. The full methodology has been described previously.[12]

Screening tests for hyperhomocysteinemia

Most assays measure levels of total homocysteine (tHcy) (protein-bound and complexed moieties)[13] in the fasting state or 4–6 hours after an oral methionine load (0.1 mg/kg).[7] High-pressure liquid chromatography, the most common method, has a coefficient of variation of 3%–11%.[13] Samples must be placed immediately on ice to avoid spurious elevations in tHcy levels.[7] Furthermore, levels are falsely low in the acute phase of illness such as myocardial infarction (MI).[14] Current screening tests cost between $30 and $50; however, newer, less costly techniques for measuring tHcy levels have been developed[15] and should become readily available with time.

Aside from genetic predisposition, a number of factors raise plasma tHcy levels, including increasing age, male sex and elevated serum creatinine levels.[5–7] Drugs such as antiepileptic agents, methotrexate and nitrous oxide[6] and certain disease states such as psoriasis, acute lymphoblastic leukemia, breast cancer and hypothyroidism[5,6] also increase tHcy levels, likely through effects on vitamin status. Homocysteine is inversely correlated with serum vitamin B_6, vitamin B_{12} and folate levels.[10] Thus, in populations with a higher prevalence of vitamin B_{12} deficiency, such as elderly people,[16] the specificity of plasma tHcy as a cardiac risk factor may be reduced.

Association between homocysteine and risk of CAD events

Retrospective studies

Over 30 case–control studies have compared tHcy levels between CAD patients and healthy control subjects.[17–46] Patients with CAD had significantly higher fasting plasma tHcy levels in 22 of 27 studies[18–39] (odds ratio [OR] 1.2–10.9 after adjustment for other cardiac risk factors). Levels after methionine load were also higher in patients with CAD in 8 of 9 studies[35–42] (adjusted OR 1.3–6.7).[35,43] Measurement of serum levels yielded similar results.[17,40] Moreover, 2 meta-analyses of retrospective data[11,47] confirmed these findings: the odds ratios of CAD associated with elevated plasma tHcy levels were 1.7 (95% confidence interval [CI] 1.5–1.9) and 6.14 (95% CI 2.74–13.73). The relation between tHcy levels and the number of occluded coronary vessels was not consistent.[17,30–32]

It is possible that some other factor predisposes to both CAD and hyperhomocysteinemia. As anticipated, cardiac risk factors were more common among patients with CAD. Volunteer bias may exaggerate this difference because participants of clinical trials tend to be healthier and thus control subjects may have fewer risk factors than do people in the general population. Certain healthy behaviours, such as low caffeine intake[48] and multivitamin use,[10,35] are inversely associated with plasma tHcy levels. Homocysteine may be related to risk factors such as smoking,[35,37] hypertension,[32–35] dyslipidemia[27–29,35] and hyperglycemia;[49] however, it appears to have an independent effect[33–38] and may even interact with other factors to influence CAD risk.[19,35] In one study adjustment for plasma fibrinogen abolished the association between tHcy and CAD.[17] The relation between tHcy and other unconventional risk factors is unknown. Thus, retrospective studies can show an association but not a causal relation.

Prospective studies

Eight nested case–control studies prospectively evaluated the relation between tHcy and the occurrence of a first major CAD event[47,50–55] or new-onset angina necessitating coronary artery bypass surgery.[56] Unfortunately, these studies had conflicting findings. MI and coronary death were associated with higher tHcy levels in only 4 of 7 studies,[47,50–52] and adjustment for prevalent CAD attenuated this relation in 1 study.[52] In the MRFIT trial,[54] a minority of patients who had early CAD events had sufficient frozen plasma available to measure tHcy levels. Thus, in many cases, plasma tHcy may have been measured too far in advance. In

Table 1: Relation between plasma total homocysteine (tHcy) levels and overall mortality and death due to coronary artery disease (CAD)

Plasma tHcy level, μmol/L	No. of subjects n = 587	Overall mortality, %	Relative risk (and 95% CI)	
			Death*	CAD-related death†
< 9	130	3.8	1.0	1.0
9–14.9	372	9.9	1.9 (0.7–5.1)	2.3 (0.7–7.7)
15–19.9	59	25.4	2.8 (0.9–9.0)	2.5 (0.6–10.5)
≥ 20	26	26.9	4.5 (1.2–16.6)	7.8 (1.7–35.1)

Source: abridged from Nygård et al.[60]
Note: CI = confidence interval.
*Adjusted for age, sex, left ventricular ejection fraction, creatinine level, total cholesterol level, extent of CAD, treatment for hypertension, history of diabetes mellitus, smoking history, platelet count and use of ASA.
†Adjusted for age, sex, left ventricular ejection fraction, creatinine level, total cholesterol level and extent of CAD; p for trend = 0.01.

contrast to major CAD events, the development of angina was not related to plasma tHcy.[56]

Prospective cohort studies suggest that tHcy is a greater risk factor for major CAD events in patients with established CAD. In 2 studies[57,58] coronary events occurred more frequently in men with hyperhomocysteinemia than in men with normal tHcy levels; however, adjustment for prevalent CAD at baseline attenuated this association. In contrast, nonfasting tHcy levels were independently related to death due to cardiovascular disease (relative risk [RR] 1.52, 95% CI 1.16–1.98) and overall mortality (RR 1.54, 95% CI 1.31–1.82) in elderly men and women from the original Framingham cohort.[59] The most compelling evidence comes from Nygård and associates,[60] who prospectively followed 587 patients with significant stenosis on coronary angiography. A dose–response relation between baseline homocysteine levels and both death due to CAD and overall mortality was observed (Table 1). Similar findings were noted among patients with other forms of atherosclerosis.[61]

The evidence from the prospective studies suggests that homocysteine acts by promoting acute thromboembolic events. Few prospective studies have evaluated the role of homocysteine in the chronic progression of atherosclerosis. In the Shunt Occlusion Trial[62] graft occlusion rates 1 year after coronary artery bypass surgery were not related to preoperative tHcy levels. However, atherosclerotic changes incurred by tHcy may require longer than 1 year to develop. In summary, the evidence strongly suggests that plasma tHcy is a risk factor for acute cardiac events in patients with underlying vascular disease.

Association between genetic predisposition to hyperhomocysteinemia and CAD

Homozygosity for a mutation in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene, involved in homocysteine metabolism, is found in 4%–14% of the general population[2] and is associated with elevated plasma tHcy[63–67] levels under conditions of impaired folate status.[63–66] The importance of this mutation in the development of CAD may depend on the population. Studies involving Japanese people have consistently shown a higher prevalence of the mutation among patients with CAD,[68–71] whereas only a minority of studies involving whites detected an association.[24,36] Moreover, a relation between the MTHFR genotype and the number of occluded vessels on coronary angiography was observed in Japanese patients[68] but not in whites.[72–74] No association between the mutation and other risk factors, including a family history of premature CAD, has been shown.[73–75]

In one meta-analysis, involving almost 5000 patients from 8 studies, the homozygous mutation was associated with an increased risk of CAD (OR 1.22, 95% CI 1.01–1.47).[67] However, a larger meta-analysis of 23 studies failed to demonstrate an association between the MTHFR genotype and either CAD (OR 1.11, 95% CI 0.91–1.37) or any cardiovascular end point (OR 1.12, 95% CI 0.92–1.37).[76] A Japanese study found a declining prevalence of the MTHFR mutation with increasing age; this finding suggests that the mutation may lead to early deaths due to cardiovas-

Table 2: Summary table of recommendations (screening and treatment of hyperhomocysteinemia)

Manoeuvre	Effectiveness	Level of evidence*	Recommendation*
Screening for plasma tHcy level†	Currently available techniques for measuring tHcy levels have a coefficient of variation of 2%–11%. Testing is restricted to research centres		
General population	An association between tHcy levels and CAD risk has been shown (the majority of studies measured fasting tHcy levels). However, the effect of screening on patient outcomes is unknown	Cohort[59] and case–control[17–42,47,50–52] studies (II-2)	Insufficient evidence to recommend for or against screening for hyperhomocysteinemia in the general population (grade C)
People at high risk for CAD events	Prospective studies have shown a more consistent relation between tHcy levels and CAD events in patients with pre-existing CAD. Again, the effect of screening on patient outcomes is unknown	Cohort[57–61] and case–control[17–42,50,52] studies (II-2)	Insufficient evidence to recommend for or against screening for hyperhomocysteinemia in high-risk populations (grade C)‡
Vitamin therapy	Treatment with folic acid (alone or with vitamin B_{12}) is effective in lowering plasma tHcy levels, whereas vitamin B_6 lowers post-methionine load levels. There are no completed studies regarding the effectiveness of treatment on clinical outcomes	RCTs[89,96–99] (I), cohort study[100] (II-2) and uncontrolled studies[90–95,101] (II-3)	Insufficient evidence to recommend for or against treatment of hyperhomocysteinemia with vitamin therapy (grade C)§

Note: RCTs = randomized controlled trials.
*See Appendix 1 for definitions of the levels of evidence and grades of recommendations.
†In fasting state or after methionine load.
‡Screening may identify individuals at higher risk of developing coronary artery disease, leading to aggressive risk factor modification. However, there is insufficient evidence to recommend screening for the purpose of treating hyperhomocysteinemia.
§Although folic acid effectively lowers plasma tHcy levels, there is insufficient evidence to support that its use would prevent CAD events.

cular disease.[77] However, the mutation does not appear to be related to longevity in whites (OR 0.87, 95% CI 0.69–1.11).[78] In light of these observations, it has been suggested that other genetic abnormalities or risk factors may interact with the MTHFR mutation to increase cardiovascular risk.[79]

Association between serum folate, vitamin B_6 or vitamin B_{12} levels and risk of CAD events

Homocysteine may simply be a nonspecific marker of vitamin deficiency. Several studies identified an inverse relation between serum folate levels and CAD events on univariate analysis; however, adjustment for plasma tHcy levels obliterated this effect.[80–82] Serum vitamin B_{12} levels have no relation to CAD; however, vitamin B_6 may be an independent risk factor. Robinson and associates[82] observed an increased risk of CAD among patients with low vitamin B_6 levels (OR 1.84, 95% CI 1.39–2.42) that remained after adjustment for plasma tHcy levels. Similarly, homocysteine remained a significant predictor of CAD after controlling for serum vitamin levels.[60,82]

Effect of vitamin therapy

Several randomized controlled trials have evaluated the

Table 3: Dietary sources of folic acid, vitamin B_6 and vitamin B_{12}

Nutrient	Recommended daily allowance	Average dietary intake by adults	Dietary sources
Folic acid	Women: 180 μg Men: 200 μg	200–300 μg	Green leafy vegetables (e.g., spinach, broccoli), legumes (e.g., lentils, chickpeas, lima beans), orange juice, oranges, cereals, breads, wheat germ
Vitamin B_6	1.6 mg	1.5 mg	Meat, poultry, fish, green leafy vegetables, legumes, seeds, potatoes, cantaloupe, milk, egg yolks, cereals, grains, wheat, wheat germ
Vitamin B_{12}	2.4 μg	4–8 μg	Beef, poultry, fish (particularly crab, oyster, salmon and herring), liver, kidney, soy, fruit juice, dairy products, egg yolks, fortified cereals, breads

Table 4: Randomized trials of homocysteine-lowering interventions currently underway

Study	Population	Start date	Sample size
Bergen Vitamin Study	Stroke (Norway)	1997	2000
Cambridge Heart Antioxidant Study (CHAOS-2)	MI, unstable angina (United Kingdom)	1998	4000
Heart Outcomes Prevention Evaluation (HOPE-2) Study	Arterial vascular disease (Canada)	1999	5000
Norwegian Study of Homocysteine Lowering with B-Vitamins in Myocardial Infarction (NORVIT)	MI (Norway)	1998	3000
Prevention with a Combined Inhibitor and Folate in Coronary Heart Disease (PACIFIC) Study	Arterial vascular disease (Australia)	1998	10 000
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH)	MI (United Kingdom)	1998	12 000
Vitamins in Stroke Prevention (VISP) Trial	Stroke (United States)	1998	3600
VITAmins TO Prevent Stroke Study (VITATOPS)	Stroke (Australia)	1999	5000
Women's Antioxidant and Cardiovascular Disease Study (WACS)	Vascular disease or high risk for vascular disease (United States)	1998	8000

Note: MI = myocardial infarction.
Source: abridged from Eikelboom et al.[107]

effect of multivitamin supplementation on fasting tHcy levels. All treatment regimens, including a combination of folic acid (1–5 mg), vitamin B_6 (5–50 mg) and vitamin B_{12} (0.02–1 mg), lowered fasting plasma tHcy levels by 20% to 50%.[83–88] Treatment response in patients with CAD was equivalent to that in healthy control subjects.[24] A meta-analysis[89] of 12 studies, involving a total of 1114 patients, revealed that folic acid (0.4–5 mg) lowered tHcy levels by 25% on average in people with or without vascular disease. Higher plasma tHcy levels and lower serum folate levels enhanced this effect. The addition of vitamin B_{12}, but not vitamin B_6, led to a further reduction in fasting tHcy levels of about 7% (95% CI 3%–10%). The effect of folic acid was maximal at 0.5 mg/d; however, 0.2 mg may be sufficient to normalize fasting tHcy levels in some patients.[90,91] Lower doses, such as 0.1 mg, appear to be ineffective.[91,92]

Although vitamin B_6 was found to have little effect on fasting plasma tHcy levels, uncontrolled studies have illustrated its utility in the treatment of hyperhomocysteinemia after methionine load. Post-load tHcy levels were found to decline by 21%–42% following treatment with vitamin B_6 (50–250 mg).[93,94] In patients who respond poorly to vitamin B_6 (up to 25%[94]), folic acid may be effective. In the majority of patients 6 weeks of treatment with single or combination therapy is sufficient to normalize tHcy levels.[95]

In a study involving young women folate from natural food sources or fortified foods had the same effect on plasma tHcy levels (12%–21% reduction) as equivalent doses of vitamin supplements.[96] However, in middle-aged men and women, breakfast cereal fortified with 666 μg of folic acid per day had a modest effect on fasting tHcy levels (10%–14% reduction),[97–99] regardless of whether vitamin B_6 or B_{12} or other micronutrients were added.[98] Thus, current recommendations by the Food and Drug Administration in the United States to fortify cereal grain products with 140 μg of folic acid per 100g serving may be insufficient to normalize elevated homocysteine levels.[99]

Prevention of CAD

Whether lowering plasma homocysteine levels will prevent CAD events is unknown because of the absence of longer randomized controlled trials with appropriate end points. Some epidemiological data suggest that folate and vitamin B_6 intake may influence the occurrence of major CAD events. The Nurses' Health Study[100] found that women who consumed more than 400 μg of folate or 3 mg of vitamin B_6 per day had a lower risk of heart disease than those with lower intake levels (adjusted RR 0.69 for folate, 95% CI 0.55–0.87, and 0.67 for vitamin B_6, 95% CI 0.53–0.85). Furthermore, an uncontrolled study showed that areas of plaque in carotid arteries regressed in 38 patients with hyperhomocysteinemia who were given daily amounts of folic acid (2.5–5 mg), vitamin B_6 (25 mg) and vitamin B_{12} (250 μg) over 4 years.[101] Similarly, in another study patients with homocystinuria who received a minimum of folic acid (5 mg) and vitamin B_6 (100–200 mg) experienced fewer vascular events (RR 0.09, 95% CI 0.02–0.38) than patients who remained untreated.[102] Although striking, findings from the latter study cannot be extrapolated to the general population because of patient differences and other methodological issues.

Recommendations

By the Canadian Task Force on Preventive Health Care

The task force's recommendations are summarized in Table 2. There is insufficient evidence to include or exclude screening of tHcy levels in any population (grade C recommendation). Screening may enable identification of patients at high risk for CAD so that other risk factors can be managed aggressively. However, laboratory testing for homocysteine is currently restricted to research centres. Moreover, testing is not yet covered by provincial health insurance, and therefore patients may be required to cover the cost.

Although folic acid effectively lowers plasma tHcy levels, there is insufficient evidence to suggest that its use would prevent CAD events (grade C recommendation). Adherence to the recommended daily allowance of dietary sources of folate and vitamins B_6 and B_{12} (Table 3) may prevent hyperhomocysteinemia due to vitamin deficiency. Once elevated tHcy levels are discovered, vitamin deficiency should be ruled out to allow specific treatment and prevention of complications, such as neurological sequelae due to vitamin B_{12} deficiency. Some authorities recommend limiting folic acid intake to 1 mg/d[103,104] or adding higher doses of vitamin B_{12} (0.2–1 mg/d)[105] because of the theoretical risk of unmasking occult vitamin B_{12} deficiency.[103]

By other groups

Guidelines from the American Heart Association[104] state that it may be reasonable to screen tHcy levels in people who are at risk for hyperhomocysteinemia (e.g., those with renal failure) or in those who have a personal or family history of premature atherosclerosis. Several experts in the area concur[5,105,106] and suggest lowering fasting tHcy levels to less than 10 μmol/L.[105] If initial treatment with dietary sources are ineffective, then supplements or fortified foods containing at least 400 μg of folic acid, 2 mg of vitamin B_6 and 6 μg of vitamin B_{12} can be used.

Research agenda

Large-scale randomized trials designed to assess the effect of folic acid therapy on cardiovascular events are underway[107] (Table 4). Thus, evidence on which to base recommendations for the treatment of hyperhomocysteinemia is forthcoming. The optimal vitamin dose and regimen, and the role of methionine-load testing in the diagnosis of

this disorder need to be clarified. Although folic acid attained through food sources alone may be insufficient to normalize elevated tHcy levels, people with low folate intake are more susceptible to hyperhomocysteinemia. Most flour and cereal products consumed by Canadians are produced domestically, where folic acid fortification is optional. Review of fortification policies will be necessary as our knowledge regarding prevention and treatment of hyperhomocysteinemia advances.

We thank Dr. Jacques Genest, Institut de Recherches Cliniques de Montréal, Montreal, and Dr. Killian Robinson, Department of Cardiology, Cleveland Clinic Foundation, Cleveland, for reviewing a draft of this manuscript. The views expressed in this report are those of the authors and the Canadian Task Force on Preventive Health Care and do not necessarily reflect the positions of reviewers.

Competing interests: None declared.

References

1. *Causes of death, 1995*. Ottawa: Statistics Canada; 1997. Cat no 84-208-XPB.
2. Brophy JM. The epidemiology of acute myocardial infarction and ischemic heart disease in Canada: data from 1976 to 1991. *Can J Cardiol* 1997;13:474-8.
3. Skovby F. Inborn errors of metabolism causing homocysteinemia and related vascular involvement. *Haemostasis* 1989;19(Suppl 1):4-9.
4. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, et al. The natural history of homocystinuria due to cystathione β-synthase deficiency. *Am J Hum Genet* 1985;37:1-31.
5. Moghadasian MH, McManus BM, Frohlich JJ. Homocyst(e)ine and coronary artery disease. Clinical evidence and genetic and metabolic background. *Arch Intern Med* 1997;157:2299-308.
6. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. *J Am Coll Cardiol* 1996;27:517-27.
7. Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. *Annu Rev Med* 1998;49:31-62.
8. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. *Arch Intern Med* 1998;158:2101-6.
9. Eichinger S, Stümpflen A, Hirschl M, Bialonczyk C, Herkner K, Stain M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. *Thromb Haemost* 1998;80:566-9.
10. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. *JAMA* 1993;270:2693-8.
11. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. *JAMA* 1995;274:1049-57.
12. Woolf SH, Battista RN, Anderson GM, Logan AG, Wang E, and the Canadian Task Force on the Periodic Health Examination. Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. *J Clin Epidemiol* 1990;43:891-905.
13. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. *Clin Chem* 1993;39:1964-79.
14. Egerton W, Silberberg J, Crooks R, Ray C, Xie L, Dudman N. Serial measures of plasma homocyst(e)ine after acute myocardial infarction. *Am J Cardiol* 1996;77:759-64.
15. Frantzen F, Faaren AL, Alfheim I, Nordhei AK. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. *Clin Chem* 1998;44:311-6.
16. Lindenbaum J, Rosenberg IH, Wilson PWF, Stabler SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. *Am J Clin Nutr* 1994;60:2-11.
17. von Eckardstein A, Malinow MR, Upson B, Heinrich J, Schulte H, Schonfeld R, et al. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. *Arterioscler Thromb* 1994;14:460-4.
18. Olszewski AJ, Szostak WB. Homocysteine content of plasma proteins in ischemic heart disease. *Atherosclerosis* 1988;69:109-13.
19. Genest J Jr, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. *J Am Coll Cardiol* 1990;16:1114-9.
20. Kang SS, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. *Am J Hum Genet* 1991;48:536-45.
21. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. *Circulation* 1995;92:2825-30.
22. Aronow WS, Ahn C. Association between plasma homocysteine and coronary artery disease in older persons. *Am J Cardiol* 1997;80:1216-8.
23. Verhoef P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, Stabler SP, et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B_6, B_{12}, and folate. *Am J Epidemiol* 1996;143:845-59.
24. Malinow MR, Nieto FJ, Kruger WD, Duell PB, Hess DL, Gluckman RA, et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. *Arterioscler Thromb Vasc Biol* 1997;17:1157-62.
25. Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, Rosenblatt DS, et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. *Arterioscler Thromb Vasc Biol* 1997;17:569-73.
26. Schwartz SM, Siscovick DS, Malinow MR, Rosendaal FR, Beverly K, Hess DL, et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. *Circulation* 1997;96:412-7.
27. Wu LL, Wu J, Hunt SC, James BC, Vincent GM, Williams RR, et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. *Clin Chem* 1994;40:552-61.
28. Malinow MR, Ducimetiere P, Luc G, Evans AE, Arveiler D, Cambien F, et al. Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease. *Atherosclerosis* 1996;126:27-34.
29. Loehrer FMT, Angst CP, Haefeli WE, Jordan PP, Ritz R, Fowler B. Low whole-blood S-adenosyl-methionine and correlation between 5-methyltetrahydrofolate and homocysteine in coronary artery disease. *Arterioscler Thromb Vasc Biol* 1996;16:727-33.
30. Kang SS, Wong PWK, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine. A possible risk factor for coronary artery disease. *J Clin Invest* 1986;77:1482-6.
31. Ubbink JB, Vermaak WJH, Bennett JM, Becker S, van Staden DA, Bissbort S. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. *Klin Wochenschr* 1991;69:527-34.
32. Montalescot G, Ankri A, Chadefaux-Vekemans B, Blacher J, Philippe F, Drobinski G, et al. Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease. *Int J Cardiol* 1997;60:295-300.
33. Dalery K, Lussier-Cacan S, Selhub J, Davignon J, Latour Y, Genest J Jr. Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B_{12}, B_6, pyridoxal phosphate, and folate. *Am J Cardiol* 1995; 75:1107-11.
34. Pancharuniti N, Lewis CA, Sauberlich HE, Perkins LL, Go RCP, Alvarez JO, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. *Am J Clin Nutr* 1994;59:940-8.
35. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. *JAMA* 1997;277:1775-81.
36. Kluijtmans LAJ, van den Heuvel LPW, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. *Am J Hum Genet* 1996;58:35-41.
37. Lolin YI, Sanderson JE, Cheng SK, Chan CF, Pang CP, Woo KS, et al. Hyperhomocysteinaemia and premature coronary artery disease in the Chinese. *Heart* 1996;76:117-22.
38. Verhoef P, Kok FJ, Kruyssen DACM, Schouten EG, Witteman JCM, Grobbee DE, et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. *Arterioscler Thromb Vasc Biol* 1997;17:989-95.
39. Israelsson B, Brattström LE, Hultberg BL. Homocysteine and myocardial infarction. *Atherosclerosis* 1988;71:227-33.
40. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. *N Engl J Med* 1991;324:1149-55.
41. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. *J Clin Invest* 1976;57:1079-82.
42. Murphy-Chutorian DR, Wexman MP, Grieco AJ, Heininger JA, Glassman E, Gaull GE, et al. Methionine intolerance: a possible risk factor for coronary artery disease. *J Am Coll Cardiol* 1985;6:725-30.
43. Donner MG, Klein GK, Mathes PB, Schwandt P, Richter WO. Plasma total homocysteine levels in patients with early-onset coronary heart disease and a low cardiovascular risk profile. *Metabolism* 1998;47:273-9.
44. Wilcken DEL, Reddy SG, Gupta VJ. Homocysteinemia, ischemic heart disease, and the carrier state for homocystinuria. *Metabolism* 1983;32:363-70.
45. Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic poly-

morphism of methylenetetrahydrofolate reductase and myocardial infarction. A case–control study. *Circulation* 1996;94:1812-4.
46. Kang S-S, Passen EL, Ruggie N, Wong PWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. *Circulation* 1993;88:1463-9.
47. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease. Results of a prospective study with implications regarding prevention. *Arch Intern Med* 1998;158:862-7.
48. Nygård O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. *Am J Clin Nutr* 1998;67:263-70.
49. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJC, Jakobs C, Bouter LM, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. *Arterioscler Thromb Vasc Biol* 1998;18:133-8.
50. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. *JAMA* 1992;268:877-81.
51. Arnesen E, Refsum H, Bønaa KH, Ueland PM, Førde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. *Int J Epidemiol* 1995;24: 704-9.
52. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JCM, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly. The Rotterdam Study. *Arch Intern Med* 1999;159:38-44.
53. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* 1998;98:204-10.
54. Evans RW, Shaten J, Hempel JD, Cutler JA, Kuller LH, for the MRFIT Research Group. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. *Arterioscler Thromb Vasc Biol* 1997;17:1947-53.
55. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. *Atherosclerosis* 1994;106:9-19.
56. Verhoef P, Hennekens CH, Allen RH, Stabler SP, Willett WC, Stampfer MJ. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. *Am J Cardiol* 1997;79:799-801.
57. Ubbink JB, Fehily AM, Pickering J, Elwood PC, Vermaak WJH. Homocysteine and ischaemic heart disease in the Caerphilly cohort. *Atherosclerosis* 1998;140:349-56.
58. Stehouwer CDA, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJM, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. *Arterioscler Thromb Vasc Biol* 1998;18:1895-901.
59. Bostom A, Silbershatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. *Arch Intern Med* 1999;159:1077-80.
60. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. *N Engl J Med* 1997;337:230-6.
61. Taylor LM Jr, Moneta GL, Sexton GJ, Schuff RA, Porter JM, and the Homocysteine and Progression of Atherosclerosis Study Investigators. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. *J Vasc Surg* 1999;29:8-21.
62. Eritsland J, Arnesen H, Seljeflot I, Abdelnoor M, Grønseth K, Berg K, et al. Influence of serum lipoprotein(a) and homocyst(e)ine levels on graft patency after coronary artery bypass grafting. *Am J Cardiol* 1994;74:1099-102.
63. Verhoef P, Kok FJ, Kluijtmans LAJ, Blom HJ, Refsum H, Ueland PM, et al. The 677C→T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. *Atherosclerosis* 1997;132:105-13.
64. Girelli D, Friso S, Trabetti E, Olivieri O, Russo C, Pessotto R, et al. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. *Blood* 1998;91:4158-63.
65. Verhoeff BJ, Trip MD, Prins MH, Kastelein JJP, Reitsma PH. The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B_{12} and on the risk of premature atherosclerosis. *Atherosclerosis* 1998;141:161-6.
66. Thuillier L, Chadefaux-Vekemans B, Bonnefont JP, Kara A, Aupetit J, Rochette C, et al. Does the polymorphism 677C-T of the 5,10-methylenetetrahydrofolate reductase gene contribute to homocysteine-related vascular disease? *J Inherit Metab Dis* 1998;21:812-22.
67. Kluijtmans LAJ, Kastelein JJP, Lindemans J, Boers GHJ, Heil SG, Bruschke AVG, et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. *Circulation* 1997;96:2573-7.
68. Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. *Circulation* 1997;95:2032-6.
69. Ou T, Yamakawa-Kobayashi K, Arinami T, Amemiya H, Fujiwara H, Kawata K, et al. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study. *Atherosclerosis* 1998;137:23-8.
70. Izumi M, Iwai N, Ohmichi N, Nakamura Y, Shimoike H, Kinoshita M. Molecular variant of 5,10-methylenetetrahydrofolate reductase is a risk factor of ischemic heart disease in the Japanese population. *Atherosclerosis* 1996;121:293-4.
71. Morita H, Kurihara H, Sugiyama T, Hamada C, Kurihara Y, Shindo T, et al. Polymorphism of the methionine synthase gene. Association with homocysteine metabolism and late-onset vascular diseases in the Japanese population. *Arterioscler Thromb Vasc Biol* 1999;19:298-302.
72. Wilcken DEL, Wang XL, Sim AS, McCredie RM. Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C_{677} T mutation. *Arterioscler Thromb Vasc Biol* 1996;16:878-82.
73. Brugada R, Marian AJ. A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. *Atherosclerosis* 1997;128:107-12.
74. Van Bockxmeer FM, Mamotte CDS, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. *Circulation* 1997;95:21-3.
75. Anderson JL, King GJ, Thomson MJ, Todd M, Bair TL, Muhlestein JB, et al. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. *J Am Coll Cardiol* 1997;30:1206-11.
76. Brattström LE, Wilcken DEL, Öhrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. The result of a meta-analysis. *Circulation* 1998;98:2520-6.
77. Matsushita S, Muramatsu T, Arai H, Matsui T, Higuchi S. The frequency of the methylenetetrahydrofolate reductase-gene mutation varies with age in the normal population. *Am J Hum Genet* 1997;61:1459-60.
78. Brattström LE, Zhang Y, Hurtig M, Refsum H, Östensson S, Fransson L, et al. A common methylenetetrahydrofolate reductase gene mutation and longevity. *Atherosclerosis* 1998;141:315-9.
79. Refsum H, Ueland PM. Recent data are not in conflict with homocysteine as a cardiovascular risk factor. *Curr Opin Lipidol* 1998;9:533-9.
80. Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. *JAMA* 1996;275:1893-6.
81. Chason-Taber L, Selhub J, Rosenberg IH, Malinow MR, Terry P, Tishler PV, et al. A prospective study of folate and vitamin B_6 and risk of myocardial infarction in US physicians. *J Am Coll Nutr* 1996;15:136-43.
82. Robinson K, Arheart K, Refsum H, Brattström L, Boers G, Ueland P, et al, for the European COMAC group. Low circulating folate and vitamin B_6 concentrations. Risk factors for stroke, peripheral vascular disease, and coronary artery disease. *Circulation* 1998;97:437-43.
83. den Heijer M, Brouwer IA, Bos GMJ, Blom HJ, van der Put NMJ, Spaans AP, et al. Vitamin supplementation reduces blood homocysteine levels. A controlled trial in patients with venous thrombosis and healthy volunteers. *Arterioscler Thromb Vasc Biol* 1998;18:356-61.
84. Woodside JV, Yarnell JWG, McMaster D, Young IS, Harmon DL, McCrum EE, et al. Effect of B-group vitamins and antioxidant vitamins on hyperhomocysteinemia: a double-blind, randomized, factorial-design, controlled trial. *Am J Clin Nutr* 1998;67:858-66.
85. Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J. Effects of vitamin B_{12}, folate, and vitamin B_6 supplements in elderly people with normal serum vitamin concentrations. *Lancet* 1995;346:85-9.
86. Ubbink JB, van der Merwe A, Vermaak WHJ, Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. *Clin Investig* 1993;71:993-8.
87. Ubbink JB, Vermaak WHJ, van der Merwe A, Becker PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. *J Nutr* 1994;124:1927-33.
88. Dierkes J, Kroesen M, Pietrzik K. Folic acid and vitamin B_6 supplementation and plasma homocysteine concentrations in healthy young women. *Int J Vitam Nutr Res* 1998;68:98-103.
89. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. *BMJ* 1998;316:894-8.
90. Guttormsen AB, Ueland PM, Nesthus I, Nygård O, Schneede J, Vollset SE, et al. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥ 40 μmol/liter). The Hordaland Homocysteine Study. *J Clin Invest* 1996;98:2174-83.
91. Ward M, McNulty H, McPartlin J, Strain JJ, Weir DG, Scott JM. Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. *Q J Med* 1997;90:519-24.
92. Jacob RA, Wu MM, Henning SM, Swendseid ME. Homocysteine increases as folate decreases in plasma of healthy men during short-term dietary folate and methyl group restriction. *J Nutr* 1994;124:1072-80.
93. Franken DG, Boers GHJ, Blom HJ, Trijbels FJM. Effect of various regimens of vitamin B_6 and folic acid on mild hyperhomocysteinaemia in vascular patients. *J Inherit Metab Dis* 1994;17:159-62.
94. Franken DG, Boers GHJ, Blom HJ, Trijbels FJM, Kloppenborg PWC. Treat-

ment of mild hyperhomocysteinemia in vascular disease patients. *Arterioscler Thromb* 1994;14:465-70.
95. Van den Berg M, Franken DG, Boers GHJ, Blom HJ, Jakobs C, Stehouwer CDA, et al. Combined vitamin B_6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. *J Vasc Surg* 1994;20:933-40.
96. Cuskelly GJ, McNulty H, McPartlin JM, Strain JJ, Scott JM. Plasma homocysteine response to folate intervention in young women. *Ir J Med Sci* 1995;164:3.
97. Schorah CJ, Devitt H, Lucock M, Dowell AC. The responsiveness of plasma homocysteine to small increases in dietary folic acid: a primary care study. *Eur J Clin Nutr* 1998;52:407-11.
98. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. *N Engl J Med* 1999;340:1449-54.
99. Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. *N Engl J Med* 1998;338:1009-15.
100. Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Manson JE, et al. Folate and vitamin B_6 from diet and supplements in relation to risk of coronary heart disease among women. *JAMA* 1998;279:359-64.
101. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyperhomocyst(e)inaemia. *Lancet* 1998;351:263.
102. Wilcken DEL, Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. *J Inherit Metab Dis* 1997;20:295-300.
103. Tucker KL, Mahnken B, Wilson PWF, Jacques P, Selhub J. Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. *JAMA* 1996;276:1879-85.
104. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases. A statement for healthcare professionals from the nutrition committee, American Heart Association. *Circulation* 1999;99:178-82.
105. Omenn GS, Beresford SAA, Motulsky AG. Preventing coronary heart disease: B vitamins and homocysteine. *Circulation* 1998;97:421-4.
106. Genest J Jr. Hyperhomocyst(e)inemia — determining factors and treatment. *Can J Cardiol* 1999;15(Suppl B):35B-38B.
107. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. *Ann Intern Med* 1999;131:363-75.

Reprint requests to: *Canadian Task Force on Preventive Health Care, Parkwood Hospital, 801 Commissioners Rd. E, London ON N6C 5J1; ctf@ctfphc.org*

Appendix 1: Canadian Task Force on Preventive Health Care levels of evidence and grades of recommendations

Levels of evidence

I	Evidence from at least one well-designed randomized controlled trial
II-1	Evidence from well-designed controlled trials without randomization
II-2	Evidence from well-designed cohort or case–control analytic studies, preferably from more than one centre or research group
II-3	Evidence from comparisons between times or places with or without the intervention; dramatic results from uncontrolled studies could be included here
III	Opinions of respected authorities, based on clinical experience; descriptive studies or reports of expert committees

Grades of recommendations

A	Good evidence to support the recommendation that the condition or manoevre be specifically considered in a periodic health examination (PHE)
B	Fair evidence to support the recommendation that the condition or manoevre be specifically considered in a PHE
C	Insufficient evidence regarding inclusion or exclusion of the condition or manoevre in a PHE, but recommendations may be made on other grounds
D	Fair evidence to support the recommendation that the condition or manoevre be specifically excluded from a PHE
E	Good evidence to support the recommendation that the condition or manoevre be specifically excluded from a PHE